Phase 1 Clinical Trial for Childhood Obesity Treatment with Tirzepatide! (H-53214)
Description
Content
Background
In response to the growing concern surrounding childhood obesity, we are thrilled to introduce a Phase 1 FDA-regulated clinical trial aimed at assessing the safety and tolerability of Tirzepatide. This phase marks a significant stride in our mission to combat childhood obesity and mitigate the related health risks.
Who is eligible to participate?
- Children between 6-11 years old
- Maximum weight allowed is 110 pounds
- BMI percent equal or exceeds the 95th percentile
Benefits of Participation:
- Contribute to pioneering research.
- Receive complimentary support sessions.
- Compensation of up to $1,400 over a 14-18 weeks duration of study participation.
Your Participation Matters:
By enrolling in this study, you assume a pivotal role in advancing our comprehension of childhood obesity and its potential treatments. We are wholeheartedly dedicated to making a positive impact on the lives of children and their families, and your contribution can play a part in shaping the future of healthcare.
To get in touch with us, please complete our contact form below or reach out to us at (713) 798-9316 or Eli-Lilly_I8F@bcm.edu.
Complete our Study Interest Contact Form:
Contact
Phone 1: 713–798–9316
IRB: H-53214
Status:
Active
Created:
